Our main expertise is chemical proteomics. We couple medicinal chemistry and bottom-up proteomics to develop proteomics-aided drug discovery.
On-bead immobilised small molecules can specifically enrich their targets, which can be identified and quantified using the multiplexing capacity of mass-spectrometry readout. From this realisation, affinity-based proteome profiling has matured into a powerful target deconvolution technology.
We push the boundaries of this approach and propose a target-agnostic drug discovery progression. The pipeline is composed of the following three key modules:
- proteome-wide screening of small molecules
- proteome-wide SAR study of pharmacophores
- selectivity profiling of candidate inhibitors
We demonstrate the feasibility and added-value of this molecule-centered strategy and contribute to expand the druggable proteome.
Current group members:
Guillaume Médard – Group leader
Polina Prokofeva – PhD student
Severin Lechner – PhD student
Luna Bergamasco – PhD student